Mechanical Ventilation

Delaying intubation and using non-invasive respiratory support first shows survival benefit in COVID-19. The elevated mortality of ventilated COVID-19 patients compared to ARDS trial benchmarks strongly suggests an underlying intravascular pathophysiology that standard ARDS ventilator protocols do not address. COVID-19 patients on mechanical ventilation show approximately 80% mortality, roughly double the 40–50% seen in landmark ARDS trial control arms. Early in the pandemic, clinicians favored rapid intubation for infection source control, a practice that was later reversed by accumulated evidence. Mechanical ventilation sustains respiratory function while the underlying pathology resolves but cannot itself repair that damage. Many COVID-19 patients tolerate significantly depressed oxygen saturations without distress, a phenomenon termed 'happy hypoxia,' and are not intubated on saturation numbers alone. Non-invasive respiratory support creates aerosolization risk to healthcare workers, requiring full PPE including face shields. Mechanical ventilation itself carries significant morbidity, which justifies accepting aerosolization risk to delay intubation. The patient was on mechan…